An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma

Chimeric antigen receptor (CAR) T cell therapies targeting single antigens have performed poorly in clinical trials for solid tumors due to heterogenous expression of tumor-associated antigens (TAAs), limited T cell persistence, and T cell exhaustion. Here, we aimed to identify optimal CARs against...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Meijie, Cheuk, Adam T., Wei, Jun S., Abdelmaksoud, Abdalla, Chou, Hsien-Chao, Milewski, David, Kelly, Michael C., Song, Young K., Dower, Christopher M., Li, Nan, Qin, Haiying, Kim, Yong Yean, Wu, Jerry T., Wen, Xinyu, Benzaoui, Mehdi, Masih, Katherine E., Wu, Xiaolin, Zhang, Zhongmei, Badr, Sherif, Taylor, Naomi, Croix, Brad St., Ho, Mitchell, Khan, Javed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374382/
https://www.ncbi.nlm.nih.gov/pubmed/35852863
http://dx.doi.org/10.1172/JCI155621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374382/
https://www.ncbi.nlm.nih.gov/pubmed/35852863
http://dx.doi.org/10.1172/JCI155621

Ejemplares similares